This website does not function properly without javascript

Welcome to the Peeper lab website

Welcome to the Peeper laboratory website. Daniel Peeper’s research group develops and uses function-based oncogenomic approaches to ask clinically relevant questions, aiming to dissect cancer-driving genetic networks for drug target and biomarker discovery. For example, we are exploring ways to enhance the activity, or avoid resistance, of currently used targeted clinical compounds. Recently, we have also begun building experimental systems to develop combinatorial targeted and immunotherapeutic therapies.


daniel



News & highlights


  • vacanciesWe have two job openings for highly motivated postdocs with a background in immunology. For more info, click here
  • mueller(December 2014) Judith's study on the effect of the MITF/AXL ratio on targeted drug sensitivity in melanoma has been published in Nature Communications
  • smit3(November 2014) Patricia's study on synthetic lethality between hypoxia and DNA damage response inhibition has been published in Cell Reports
  • vacanciesWe have two job openings for highly motivated postdocs with a background in immunology. For more info, click here
  • smit3(November 2014) Marjon's study on combining Rock1 and RAS-signalling cascase inhibition in melanoma has been published in Molecular Systems Biology
  • kaplon(May 2013) Joanna's study on OIS, metabolism and melanoma therapy published in Nature with a preview in Cell and a research watch in Cancer Discovery.
  • vacanciesWe have two job openings for highly motivated postdocs with a background in immunology. For more info, click here
  • ERCsynergy(2013) Daniel Peeper, together with five other researchers, has received a 15M€ ERC Synergy grant.



logo